0000950103-20-000857.txt : 20200121
0000950103-20-000857.hdr.sgml : 20200121
20200121192335
ACCESSION NUMBER: 0000950103-20-000857
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200116
FILED AS OF DATE: 20200121
DATE AS OF CHANGE: 20200121
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Papiernik Antoine
CENTRAL INDEX KEY: 0001768408
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38829
FILM NUMBER: 20537332
MAIL ADDRESS:
STREET 1: 5403 BETSY ROSS DRIVE
CITY: SANTA CLARA
STATE: CA
ZIP: 95054
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ShockWave Medical, Inc.
CENTRAL INDEX KEY: 0001642545
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 270494101
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5403 BETSY ROSS DRIVE
CITY: SANTA CLARA
STATE: CA
ZIP: 95054
BUSINESS PHONE: (510) 279-4262
MAIL ADDRESS:
STREET 1: 5403 BETSY ROSS DRIVE
CITY: SANTA CLARA
STATE: CA
ZIP: 95054
4
1
dp119488_4-papiernik.xml
FORM 4
X0306
4
2020-01-16
0
0001642545
ShockWave Medical, Inc.
SWAV
0001768408
Papiernik Antoine
C/O SHOCKWAVE MEDICAL, INC.
5403 BETSY ROSS DRIVE
SANTA CLARA
CA
95054
1
0
1
0
Common Stock
2020-01-16
4
S
0
57848
44.03
D
3192627
I
By Sofinnova Capital VII FCPR
Common Stock
2020-01-16
4
S
0
3611
44.56
D
3189016
I
By Sofinnova Capital VII FCPR
Common Stock
2020-01-17
4
S
0
82383
44.58
D
3106633
I
By Sofinnova Capital VII FCPR
Common Stock
2020-01-17
4
S
0
14708
45.00
D
3091925
I
By Sofinnova Capital VII FCPR
Common Stock
2020-01-21
4
S
0
38836
42.67
D
3053089
I
By Sofinnova Capital VII FCPR
Common Stock
2020-01-21
4
S
0
53439
43.88
D
2999650
I
By Sofinnova Capital VII FCPR
Common Stock
2020-01-21
4
S
0
77175
44.74
D
2922475
I
By Sofinnova Capital VII FCPR
Represents shares directly held by Sofinnova Capital VII FCPR, reported by Sofinnova Capital VII FCPR on a separate Form 4. The reporting person is one of the managing partners of Sofinnova Partners SAS, a French corporation and the management company of Sofinnova Capital VII FCPR. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest.
The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $43.42 to $44.34. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $44.48 to $44.63. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $43.98 to $44.97. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $44.98 to $45.02. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $42.19 to $43.18. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $43.19 to $44.18. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $44.19 to $45.00. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by Sofinnova Capital VII FCPR on 12/06/2019.
/s/ Trinh Phung, as attorney-in-fact for Antoine Papiernik
2020-01-21